Русский
Nederlandse taal
Deutsch
Francés
한국어
Português
Español
日本語
ไทย
Sub Skin Cross Linked Hyaluronic Acid Dermal Filler
Ingredient: 24mg/ml hyaluronic acid
Specification: 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml
Package: Syringe
Recommended use: 1-3 pcs, 12 months apart
Application Area:Chest, buttocks and other filled and shaped body parts
Product Introduction：
The series of cross linked sodium hyaluronic acid gels meet the multi-dimensional needs of the face through differentiated design: single products achieve natural shaping with excellent tissue integration; Double products show strong support with low thrust force; The soft texture created by micro-crosslinking technology specializes in shallow grain repair, and the lower crosslinking degree and elastic modulus significantly reduce the risk of pico formation compared to the doll needle. Benchmarking international brands, its long-term performance is more prominent.
Product Display：
Product Details:
Type | Sub skin |
Ingredient | Cross Linked Hyaluronic Acid Dermal Filler |
Specification | 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml |
Cross Link | BDDE chemical cross link |
Texture | Gel |
Elasticity | 550 Pa-700 Pa |
Viscosity | 180 Pa-280 Pa |
Mean particle size | 450μm-650μm |
Effective content | 24mg/mL |
Cross linker residue | No,or≤0.5ug/g |
Protein residue | ≤20μg/g |
Endotoxin content | <0.5EU/mL |
Swelling degree | 20-35 |
Extruding force | 20N-30N |
Application area | Chest, buttocks and other filled and shaped body parts |
Package | Syringe |
Stoarge | Room temperature (1-25ºC), cool and dry place |
Recommended | 1-3 pcs (vary with each individual |
Recommended interval | 12 month |
Product Package:
Customer Feedback:
Raw Material Advantages：
1. Cross-linking enhances HA's capacity for neocollagenesis by providing prolonged mechanical stimulation to dermal fibroblasts.
2. Ophthalmologic formulations utilizing CLHA achieve prolonged ocular surface retention times compared to linear HA solutions.
Development Process:
Company Introduction:
Specializing in advanced implant technologies since 2014, Jinan Grandwill Medical Technology operates China's first integrated medical device campus featuring:
4 ISO Class 5 cleanrooms
High-pressure sterilization tunnels
Xiling bottle filling systems
FDA-audited quality management
Our 11-patent portfolio supports production of CE-marked hemostatic powders and Class II/III devices, with real-time residual monitoring ensuring <0.01ppm BDDE levels.
